Search results
Results from the WOW.Com Content Network
Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, for early puberty, or as part of transgender hormone therapy. [10] [11] It is given by injection into a muscle or under the skin. [10]
A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...
Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive ...
Olivia Munn is taking temporary menopause-inducing medication to prevent breast cancer recurrence. ... breast cancer survivors are on these medications for an average of 4.04 years. Minkin says ...
Kathleen I. Pritchard, CM is the head of oncology at Sunnybrook Health Sciences Centre in Toronto, Canada, [1] specializing in breast cancer therapies, and leading the clinical trials division of the centre. [2] She has authored numerous studies on women's health, breast cancer, hormone replacement therapy, public health, and research ...
Moreover, breast cancer risk is heightened following use of the combined oral contraceptive pill and combined hormone replacement therapy. [4] Armed with this evidence that endogenous and exogenous changes in estrogen and progesterone levels modulate the risk of breast cancer, it is apparent that hormones can play a key role in breast cancer.
A 2015 Cochrane review found that NSAA monotherapy for prostate cancer had a greater risk of treatment discontinuation due to adverse effects than monotherapy with a GnRH agonist or surgical castration (RR = 1.82). [122] This included a greatly increased risk of breast pain (RR = 22.97) and gynecomastia (RR = 8.43). [122]
The rate of cancer recurrence is determined by many factors, including age, sex, cancer type, treatment duration, stage of advancement, grade of original tumor, and cancer-specific risk factors. [2] [3] [4] If recurrent cancer has already moved to other body parts or has developed chemo-resistance then it may be more aggressive than original ...